EtDO-P4

• UNSPSC Description:

  EtDO-P4 is a nanomolar inhibitor of glycosphingolipid (GSL) synthesis. EtDO-P4 suppresses activation of the EGFR-induced ERK pathway and various receptor tyrosine kinases (RTKs). EtDO-P4 can be used for various types of cancer, including Burkitt’s lymphoma[1].

• Target Antigen:

  ERK

• Type:

  Reference compound

• Related Pathways:

  MAPK/ERK Pathway;Stem Cell/Wnt

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/etdo-p4.html

• Purity:

  98.75

• Solubility:

  DMSO : 100 mg/mL (ultrasonic;warming;heat to 80°C)

• Smiles:

  O[C@H](C1=CC=C2C(OCCO2)=C1)[C@H](NC(CCCCCCCCCCCCCCC)=O)CN3CCCC3

• Molecular Weight:

  516.76

• References & Citations:

  [1]Seung-Yeol Park, et al. Globoside promotes activation of ERK by interaction with the epidermal growth factor receptor. Biochim Biophys Acta. 2012 Jul;1820(7):1141-8.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  245329-78-6